Institutional Investors Positive on Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Logo

Sentiment for Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals Inc (NASDAQ:PTLA) institutional sentiment increased to 2.04 in Q1 2019. Its up 1.14, from 0.9 in 2018Q4. The ratio is positive, as 100 funds started new or increased equity positions, while 49 decreased and sold equity positions in Portola Pharmaceuticals Inc. The funds in our partner’s database now possess: 61.89 million shares, down from 63.72 million shares in 2018Q4. Also, the number of funds holding Portola Pharmaceuticals Inc in their top 10 equity positions increased from 3 to 4 for an increase of 1. Sold All: 9 Reduced: 40 Increased: 54 New Position: 46.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $2.09 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

The stock decreased 0.23% or $0.07 during the last trading session, reaching $30.52. About 1.75M shares traded or 55.60% up from the average. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has declined 24.87% since August 15, 2018 and is downtrending. It has underperformed by 24.87% the S&P500.

Fernwood Investment Management Llc holds 7.16% of its portfolio in Portola Pharmaceuticals, Inc. for 387,011 shares. Cadian Capital Management Lp owns 3.97 million shares or 5.38% of their US portfolio. Moreover, Highland Capital Management Lp has 3.37% invested in the company for 1.56 million shares. The Florida-based Harvey Capital Management Inc has invested 2.65% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 609,357 shares.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Ratings analysis reveals 75% of Portola Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Portola Pharma, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $3500 while the high is $50. The stock’s average target of $40.50 is 32.70% above today’s ($30.52) share price. PTLA was included in 9 notes of analysts from March 4, 2019. As per Monday, March 4, the company rating was maintained by Citigroup. The firm has “Neutral” rating by Credit Suisse given on Monday, August 5. The stock has “Buy” rating by Morgan Stanley on Monday, March 4. Credit Suisse maintained it with “Hold” rating and $35 target in Monday, March 4 report. The rating was maintained by Oppenheimer with “Buy” on Monday, March 4.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: which released: “Portola Pharmaceuticals Enters Oversold Territory (PTLA) – Nasdaq” on May 17, 2019, also with their article: “Portola Pharma (PTLA) Prices 8.04M Share Common Offering at $28/Sh –” published on August 14, 2019, published: “Portola Pharmaceuticals beats by $0.09, beats on revenue – Seeking Alpha” on May 08, 2019. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: and their article: “7 Stocks To Watch For August 13, 2019 – Benzinga” published on August 13, 2019 as well as‘s news article titled: “A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Consumer Price Index – Benzinga” with publication date: August 13, 2019.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.